Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.51 |
| ▸ | MAOA | P21397 | 16/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288580 | 0.92 | MAOA (0.51) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL4281773 | 0.82 | MAOB (0.51) | MAOBMAOADRD2DRD4DRD3 | |
| SCHEMBL4291445 | 0.79 | TSHR (0.41) | MAOBMAOA | |
| SCHEMBL4285854 | 0.78 | MAOB (0.49) | MAOBMAOA | |
| SCHEMBL4281703 | 0.78 | RAB9A (0.44) | DRD2DRD3 | |
| SCHEMBL4752778 | 0.78 | RAB9A (0.44) | DRD2DRD3 | |
| SCHEMBL4294977 | 0.78 | NPC1 (0.45) | DRD3 | |
| SCHEMBL3493396 | 0.77 | TEAD1 (0.46) | — | |
| SCHEMBL4282373 | 0.77 | L3MBTL1 (0.47) | — | |
| SCHEMBL4751897 | 0.77 | L3MBTL1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAOB 550/4885MAOA 660/4885DRD2 3802/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAOB 550/4885MAOA 660/4885DRD2 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.